|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.87 USD | -0.76% |
|
-1.79% | +42.00% |
| Jun. 09 | Royalty Pharma plc Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 04:00 PM | |
| Jun. 09 | GSK buys cancer drug developer Nuvalent for USD10.6 billion | AN |
| Market Cap | 24.32B 21.01B 19.36B 18.12B 33.96B 2,312B 34.48B 229B 89.12B 1,125B 91.28B 89.34B 3,896B | P/E Ratio 2026 * |
21.5x | P/E Ratio 2027 * | 14.7x |
|---|---|---|---|---|---|
| Enterprise Value | 33.37B 28.82B 26.56B 24.86B 46.59B 3,172B 47.32B 314B 122B 1,544B 125B 123B 5,346B | EV / Sales 2026 * |
9.73x | EV / Sales 2027 * | 9.17x |
| Free-Float |
71.47% | Yield 2026 * |
1.79% | Yield 2027 * | 1.94% |
Last Transcript: Royalty Pharma plc
| 1 day | -0.76% | ||
| 1 week | -1.79% | ||
| Current month | -1.60% | ||
| 1 month | +2.75% | ||
| 3 months | +20.20% | ||
| 6 months | +42.93% | ||
| Current year | +42.00% |
| 1 week | 54.35 |  | 56.23 |
| 1 month | 51.81 | | 56.5 |
| Current year | 38.29 | | 56.5 |
| 1 year | 34.08 | | 56.5 |
| 3 years | 24.05 | | 56.5 |
| 5 years | 24.05 | | 56.5 |
| 10 years | 24.05 | | 56.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pablo Legorreta
CEO | Chief Executive Officer | 62 | 1995-12-31 |
Terrance Coyne
DFI | Director of Finance/CFO | 44 | 2009-12-31 |
Eric Schneider
CTO | Chief Tech/Sci/R&D Officer | - | 2023-09-20 |
| Director | Title | Age | Since |
|---|---|---|---|
Pablo Legorreta
CHM | Chairman | 62 | 2020-03-31 |
Gregory Norden
BRD | Director/Board Member | 68 | 2020-02-10 |
Bonnie Bassler
BRD | Director/Board Member | 63 | 2020-06-15 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| Jun. 04 | Free | Director | 4,545 | 0.0010% | ||
| Jun. 04 | Free | Director | 4,545 | 0.0010% | ||
| Jun. 04 | Free | Director | 4,545 | 0.0010% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.76% | -1.79% | +57.49% | +70.67% | 24.32B | |
| -2.41% | +0.14% | +38.28% | +153.06% | 1,010B | |
| +1.07% | +3.48% | +53.32% | +49.09% | 580B | |
| +1.32% | +0.22% | +19.18% | +67.17% | 402B | |
| -0.17% | 0.00% | +21.28% | +19.14% | 330B | |
| -0.18% | +3.78% | +26.37% | +34.76% | 281B | |
| -0.67% | -3.09% | +23.59% | +14.41% | 280B | |
| -0.94% | +4.87% | -42.73% | -48.34% | 197B | |
| +0.32% | +1.61% | +20.32% | +59.80% | 192B | |
| -0.22% | -2.76% | +14.19% | +61.12% | 156B | |
| Average | -0.26% | +0.58% | +23.13% | +48.09% | 345.31B | |
| Weighted average by Cap. | -0.50% | +1.02% | +28.22% | +70.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.43B 2.96B 2.73B 2.56B 4.79B 326B 4.86B 32.24B 12.57B 159B 12.87B 12.6B 550B | 3.66B 3.16B 2.91B 2.73B 5.11B 348B 5.19B 34.39B 13.41B 169B 13.73B 13.44B 586B |
| Net income | 1.6B 1.38B 1.27B 1.19B 2.23B 152B 2.26B 15B 5.85B 73.87B 5.99B 5.86B 256B | 2.2B 1.9B 1.75B 1.64B 3.07B 209B 3.12B 20.67B 8.06B 102B 8.25B 8.08B 352B |
| Net Debt | 9.05B 7.82B 7.2B 6.74B 12.64B 860B 12.83B 85.05B 33.16B 419B 33.96B 33.24B 1,450B | 9.22B 7.96B 7.34B 6.87B 12.87B 876B 13.07B 86.66B 33.79B 427B 34.61B 33.87B 1,477B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-12 | 54.87 $ | -0.76% | 3,185,529 |
| 26-06-11 | 55.29 $ | +1.41% | 3,073,046 |
| 26-06-10 | 54.52 $ | -2.00% | 2,228,943 |
| 26-06-09 | 55.63 $ | +1.40% | 3,747,016 |
| 26-06-08 | 54.86 $ | -1.81% | 3,714,692 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RPRX Stock
Select your edition
All financial news and data tailored to specific country editions
